Joshua D Niznik1,2, Xinhua Zhao2,3, Meiqi He3, Sherrie L Aspinall2,3,4, Joseph T Hanlon2,5, David Nace5, Joshua M Thorpe2,6, Carolyn T Thorpe2,6. 1. Department of Medicine, Division of Geriatric Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. 2. VA Pittsburgh Healthcare System, Center for Health Equity Research and Promotion, University Drive (151C), Pittsburgh, Pennsylvania, USA. 3. University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA. 4. VA Center for Medication Safety, Hines, Illinois, USA. 5. Geriatric Division, Kaufmann Medical Building, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 6. University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
Abstract
INTRODUCTION: We evaluated the impact of deprescribing acetylcholinesterase inhibitors (AChEIs) on aggressive behaviors and incident antipsychotic use in nursing home (NH) residents with severe dementia. METHODS: We conducted a retrospective study of Medicare claims, Part D, Minimum Data Set for NH residents aged 65+ with severe dementia receiving AChEIs in 2016. Aggressive behaviors were measured using the aggressive behavior scale (ABS; n = 30,788). Incident antipsychotic prescriptions were evaluated among antipsychotic non-users (n = 25,188). Marginal structural models and inverse probability of treatment weights were used to evaluate associations of AChEI deprescribing and outcomes. RESULTS: The severity of aggressive behaviors was low at baseline (mean ABS = 0.5) and was not associated with deprescribing AChEIs (0.002 increase in ABS, P = .90). Incident antipsychotic prescribing occurred in 5.1% of residents and was less likely with AChEI deprescribing (adjusted odds ratio = 0.52 [0.40-0.68], P <.001]). DISCUSSION: Deprescribing AChEIs was not associated with a worsening of aggressive behaviors or incident antipsychotic prescriptions.
INTRODUCTION: We evaluated the impact of deprescribing acetylcholinesterase inhibitors (AChEIs) on aggressive behaviors and incident antipsychotic use in nursing home (NH) residents with severe dementia. METHODS: We conducted a retrospective study of Medicare claims, Part D, Minimum Data Set for NH residents aged 65+ with severe dementia receiving AChEIs in 2016. Aggressive behaviors were measured using the aggressive behavior scale (ABS; n = 30,788). Incident antipsychotic prescriptions were evaluated among antipsychotic non-users (n = 25,188). Marginal structural models and inverse probability of treatment weights were used to evaluate associations of AChEI deprescribing and outcomes. RESULTS: The severity of aggressive behaviors was low at baseline (mean ABS = 0.5) and was not associated with deprescribing AChEIs (0.002 increase in ABS, P = .90). Incident antipsychotic prescribing occurred in 5.1% of residents and was less likely with AChEI deprescribing (adjusted odds ratio = 0.52 [0.40-0.68], P <.001]). DISCUSSION: Deprescribing AChEIs was not associated with a worsening of aggressive behaviors or incident antipsychotic prescriptions.
Authors: Debra Saliba; Joan Buchanan; Maria Orlando Edelen; Joel Streim; Joseph Ouslander; Dan Berlowitz; Joshua Chodosh Journal: J Am Med Dir Assoc Date: 2012-07-15 Impact factor: 4.669
Authors: Emily Reeve; Barbara Farrell; Wade Thompson; Nathan Herrmann; Ingrid Sketris; Parker J Magin; Lynn Chenoweth; Mary Gorman; Lyntara Quirke; Graeme Bethune; Sarah N Hilmer Journal: Med J Aust Date: 2019-02-16 Impact factor: 7.738
Authors: Ashok J Bharucha; Mihnea Vasilescu; Mary Amanda Dew; Amy Begley; Scott Stevens; Howard Degenholtz; Howard Wactlar Journal: J Am Med Dir Assoc Date: 2008-04-08 Impact factor: 4.669
Authors: Claudia Cooper; Naaheed Mukadam; Cornelius Katona; Constantine G Lyketsos; Dan Blazer; David Ames; Peter Rabins; Henry Brodaty; Carlos de Mendonça Lima; Gill Livingston Journal: Am J Geriatr Psychiatry Date: 2013-01-22 Impact factor: 4.105
Authors: Samuel W Terman; Joshua D Niznik; Geertruida Slinger; Willem M Otte; Kees P J Braun; Carole E Aubert; Wesley T Kerr; Cynthia M Boyd; James F Burke Journal: BMC Neurol Date: 2022-09-01 Impact factor: 2.903